


AETNA BETTER HEALTH® Coverage Policy/Guideline			
Name:	Reyvow	Page:	1 of 2
Effective Date:	1/13/2025	Last Review Date:	11/26/2024
Applies to:	<input checked="" type="checkbox"/> Illinois <input checked="" type="checkbox"/> Maryland	<input checked="" type="checkbox"/> Florida Kids <input checked="" type="checkbox"/> Pennsylvania Kids	<input checked="" type="checkbox"/> New Jersey <input type="checkbox"/> Virginia

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Reyvow (lasmiditan) under the patient's prescription drug benefit.

Description:

Reyvow is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use

Reyvow is not indicated for the preventive treatment of migraine.

Applicable Drug List:

Reyvow

Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for the acute treatment of migraine with or without aura in an adult patient

AND

- The patient has experienced an inadequate treatment response or an intolerance to TWO triptan 5-HT₁ receptor agonists

OR

- The patient has a contraindication that would prohibit a trial of triptan 5-HT₁ receptor agonists

AND

- If additional quantities are being requested, medication overuse headache has been considered and ruled out

AND

- The patient is currently using migraine prophylactic therapy
[Note: Examples of prophylactic therapy are divalproex sodium, topiramate, valproate sodium, metoprolol, propranolol, timolol, atenolol, nadolol, amitriptyline, venlafaxine.]

OR

- The patient is unable to take migraine prophylactic therapy due to an inadequate treatment response, intolerance, or contraindication



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Reyvow

Page: 2 of 2

Effective Date: 1/13/2025

Last Review Date: 11/26/2024

Applies to: ☒ Illinois
☒ Maryland

☒ Florida Kids
☒ Pennsylvania Kids

☒ New Jersey
☐ Virginia

[Note: Examples of prophylactic therapy are divalproex sodium, topiramate, valproate sodium, metoprolol, propranolol, timolol, atenolol, nadolol, amitriptyline, venlafaxine.]

Quantity Limits apply.

Approval Duration and Quantity Restrictions:

Approval: 12 months

Quantity Level Limit:

- Initial Limits:
 - Reyvow 50 mg = 4 tablets / 25 days
 - Reyvow 100 mg = 8 tablets / 25 days
- Post Limits:
 - Reyvow 50 mg = 8 tablets / 28 days
 - Reyvow 100 mg = 16 tablets / 25 days

References:

1. Reyvow [package insert]. Indianapolis, Indiana: Lilly USA, LLC; September 2022.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed April 1, 2024.
3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 04/1/2024).
4. American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021-1039.
5. Charles A, Digre K, Goadsby P, et al. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Headache. 2024;00:1-9.
6. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee and the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337-1346.